Hypoxia inducible factor 1 subunit alpha
Hypoxia-inducible factor-1α (HIF-1α) is the oxygen-sensitive regulatory subunit of the heterodimeric transcription factor HIF-1, which serves as the master regulator of cellular and systemic responses to hypoxia in mammalian tissues.
Hypoxia-inducible factor-1α (HIF-1α) is the oxygen-sensitive regulatory subunit of the heterodimeric transcription factor HIF-1, which serves as the master regulator of cellular and systemic responses to hypoxia in mammalian tissues. Under normoxic conditions, HIF-1α is continuously synthesized but rapidly targeted for proteasomal degradation through hydroxylation by prolyl hydroxylases — including EGLN2 (PHD1) — which marks the protein for recognition by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex. When oxygen tension falls, prolyl hydroxylase activity is suppressed, HIF-1α accumulates, translocates to the nucleus, and dimerizes with the constitutively expressed HIF-1β subunit to activate transcription of hundreds of target genes bearing hypoxia-response elements (HREs). Key transcriptional targets include vascular endothelial growth factor A (VEGFA), which drives angiogenesis; glycolytic enzymes such as hexokinase (HK2); and cytokines including Interleukin-6 (IL-6). Through these programs, HIF-1α coordinates oxygen delivery, metabolic reprogramming, and immune modulation in both physiological and pathological settings.
The biological significance of HIF-1α spans a wide spectrum of disease contexts. In oncology, HIF-1α is constitutively stabilized in solid tumors by the hypoxic, lactate-rich tumor microenvironment, where it promotes glycolysis via the HIF-1α/HK2 axis, suppresses anti-tumor immunity through upregulation of CD274 molecule and expansion of regulatory T cells, and enhances metastatic potential through targets such as MMP-9. Beyond cancer, HIF-1α plays critical roles in cardiovascular disease, ischemia-reperfusion injury, wound healing, hematopoiesis, and tissue repair. Its broad involvement in disease pathophysiology has made it both a therapeutic target — where inhibition is sought in cancer — and a potential therapeutic effector, where its activation is harnessed to promote tissue vascularization and regeneration.
Where the papers sit
14 papers from the last 6 months study hypoxia inducible factor 1 subunit alpha directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 2 observational · 11 preclinical · 1 unclassified
Themes 3 themes
-
HIF-Driven Tissue Injury
Hypoxia-linked injury is repeatedly tied to ferroptosis, lipid peroxidation, and HIF-1α signaling across cancer and nonmalignant tissues. In breast cancer, p53–p300 suppression of the HIF-1α/TFRC axis is associated with reduced ferroptosis and doxorubicin resistance. Other work connects HIF-1α/HO-1 to nanoplastic-associated ovarian injury and sustained HIF-1α to osteoarthritis, while fibrosis and neurovascular protection remain context-dependent. Biomarker studies in periodontitis broaden the clinical interest, but no single intervention or endpoint dominates.
6 papers · 42.9%
-
Hypoxic Metabolic Reprogramming
Hypoxia is being framed as a metabolic-immune state, with lactate, fatty-acid oxidation, and epigenetic remodeling recurring across disease contexts. CCR5hi monocytes link metabolism to trained immunity in sepsis, while tendinopathy work uses pathway-defined tenocyte states to seek targeted treatment. In colorectal cancer, EFHD2-driven lactate signaling through HMGB1 and HIF-1α supports DNA repair, immunosuppression, and radioresistance. 2-methoxyestradiol provides a pharmacologic route for HIF-linked lung cancer models, but the set does not establish a common clinical strategy.
4 papers · 28.6%
-
Others — HIF-Related Disease Mechanisms
Inflammatory and metabolic biomarkers are being explored in ART-treated HIV, canine disc disease, colon cancer, and gallstone formation. IL-6, CRP, fibrinogen, and HIF-1α recur as disease-associated readouts, but their clinical roles differ across settings. Synthetic benzimidazoles pursue direct HIF-1α inhibition for colon cancer, whereas emodin targets gut flora and hepatic HIF1α in gallstone models. The shared HIF/inflammation vocabulary does not resolve into one biological question or therapeutic direction.
4 papers · 28.6%
Papers
The 14 papers from the last 6 months that study hypoxia inducible factor 1 subunit alpha directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
HIF-Driven Tissue Injury (6)
- P53 Competitively Binds P300 to Suppress HIF-1α/TFRC-Mediated Ferroptosis and Promote Doxorubicin Resistance in Breast Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 18 Aug 2026 PMID 42610471
- Diagnostic accuracy and smoking-driven modulation of salivary MMP-8, MMP-9, and HIF-1α in stage III grade B/C periodontitis: a cross-sectional study. Clinical oral investigations · 15 Aug 2026 PMID 42603195
- Sustained Hypoxia-Inducible Factor 1-Alpha Accumulation Disrupts the Articular Niche to Promote Osteoarthritis Pathogenesis. Aging cell · 24 Jun 2026 PMID 42337938
- Maternal exposure to polystyrene nanoplastics triggers ovarian injury in mice offspring: Ferroptosis mediated by the HIF-1α/HO-1 pathway. Reproductive toxicology (Elmsford, N.Y.) · 12 Jun 2026 PMID 42285443
- Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139
- Effects of obacunone against myocardial fibrosis: Mechanistic insights from network pharmacology and experimental validation. European journal of pharmacology · 29 May 2026 PMID 42214778
Hypoxic Metabolic Reprogramming (4)
- Metabolic-pathway-based classification of tendinopathy reveals a precise therapeutic strategy targeting chondro-modulatory tenocytes. Bone research · 27 Aug 2026 PMID 42660868
- Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
- 2-methoxyestradiol is effective in 2D and 3D models of NCI-H2170 lung squamous cell carcinoma cells. PloS one · 4 Aug 2026 PMID 42550820
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
Others — HIF-Related Disease Mechanisms (4)
- Beyond traditional criteria: CRP and fibrinogen as biomarkers of metabolic syndrome in ART-treated people living with HIV and their association with HIF-1α rs11549465. PloS one · 8 Sept 2026 PMID 42709845
- Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC-1 as HIF-1α Inhibitor That Possess Anti-Colon Cancer Potential. Drug development research · 8 Jul 2026 PMID 42418254
- Clinical investigation of plasma HIF-1α and inflammatory biomarkers in dogs with thoracolumbar intervertebral disc disease receiving acupuncture treatment. Veterinary research communications · 29 Jun 2026 PMID 42371222
- Emodin inhibits the formation of gallstones by affecting the intestinal flora and expression of hepatic HIF1α. International immunopharmacology · 24 May 2026 PMID 42177905
By study type
Observational studies and case reports (2)
- Beyond traditional criteria: CRP and fibrinogen as biomarkers of metabolic syndrome in ART-treated people living with HIV and their association with HIF-1α rs11549465. PloS one · 8 Sept 2026 PMID 42709845
- Diagnostic accuracy and smoking-driven modulation of salivary MMP-8, MMP-9, and HIF-1α in stage III grade B/C periodontitis: a cross-sectional study. Clinical oral investigations · 15 Aug 2026 PMID 42603195
Preclinical: animal, cell and lab studies (11)
- Metabolic-pathway-based classification of tendinopathy reveals a precise therapeutic strategy targeting chondro-modulatory tenocytes. Bone research · 27 Aug 2026 PMID 42660868
- Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
- P53 Competitively Binds P300 to Suppress HIF-1α/TFRC-Mediated Ferroptosis and Promote Doxorubicin Resistance in Breast Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 18 Aug 2026 PMID 42610471
- 2-methoxyestradiol is effective in 2D and 3D models of NCI-H2170 lung squamous cell carcinoma cells. PloS one · 4 Aug 2026 PMID 42550820
- Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC-1 as HIF-1α Inhibitor That Possess Anti-Colon Cancer Potential. Drug development research · 8 Jul 2026 PMID 42418254
- Clinical investigation of plasma HIF-1α and inflammatory biomarkers in dogs with thoracolumbar intervertebral disc disease receiving acupuncture treatment. Veterinary research communications · 29 Jun 2026 PMID 42371222
- Sustained Hypoxia-Inducible Factor 1-Alpha Accumulation Disrupts the Articular Niche to Promote Osteoarthritis Pathogenesis. Aging cell · 24 Jun 2026 PMID 42337938
- Maternal exposure to polystyrene nanoplastics triggers ovarian injury in mice offspring: Ferroptosis mediated by the HIF-1α/HO-1 pathway. Reproductive toxicology (Elmsford, N.Y.) · 12 Jun 2026 PMID 42285443
- Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139
- Effects of obacunone against myocardial fibrosis: Mechanistic insights from network pharmacology and experimental validation. European journal of pharmacology · 29 May 2026 PMID 42214778
- Emodin inhibits the formation of gallstones by affecting the intestinal flora and expression of hepatic HIF1α. International immunopharmacology · 24 May 2026 PMID 42177905
Unclassified: not yet indexed with MeSH (1)
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.